The therapeutic effect of SGLT2 inhibitors in HF was first demonstrated in the empagliflozin cardiovascular outcome event trial in Type 2 diabetes mellitus patients removing excess glucose (EMPA-REG OUTCOME) trial [50] where it was noted that there was a significant reduction in the secondary endpoint of HF hospitalizations when compared with placebo. Here, SLC5A2 is linked to type 2 diabetes mellitus.